CareDx Inc

For the period ended Dec 31, 2024. Filed Feb 28, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Feb 28, 2025

CDNA$84.42+7.5%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations

(In thousands, except share and per share data)

	Year Ended December 31,
	2024	2023	2022
Revenue:
Testing services revenue	$249,381	$209,685	$263,748
Product revenue	40,783	33,517	29,251
Patient and digital solutions	43,621	37,122	28,794
Total revenue	333,785	280,324	321,793
Operating expenses:
Cost of testing services	55,611	57,642	72,286
Cost of product	23,381	18,379	17,639
Cost of patient and digital solutions	30,638	25,978	22,287
Research and development	72,405	81,866	90,388
Sales and marketing	81,718	83,334	96,027
General and administrative	123,784	117,868	100,397
Restructuring costs	1,783	2,320	—
Litigation expense	(96,300)	96,300	—
Total operating expenses	293,020	483,687	399,024
Income (loss) from operations	40,765	(203,363)	(77,231)
Other income (expense):
Interest income, net	11,765	11,867	3,762
Change in estimated fair value of common stock warrant liability	—	10	107
Other income (expense), net	329	1,343	(2,872)
Total other income	12,094	13,220	997
Income (loss) before income taxes	52,859	(190,143)	(76,234)
Income tax expense	(310)	(141)	(379)
Net income (loss)	$52,549	$(190,284)	$(76,613)
Net income (loss) per share (Note 3):
Basic	$1.00	$(3.54)	$(1.44)
Diluted	$0.93	$(3.54)	$(1.44)
Weighted-average shares used to compute net income (loss) per share:
Basic	52,773,247	53,764,705	53,321,625
Diluted	56,620,590	53,764,705	53,321,625

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.